Multiple-agent Therapy with Metronomic Xeloda® and Nexavar® Promising for Metastatic Renal Cell Carcinoma (03/12/2010)
Researchers from Spain have reported: “Maximum tolerated dose chemotherapy followed by metronomic chemotherapy” is a promising approach for treatment of patients with metastatic renal cell carcinoma (RCC). The details of this study were published early online in Lancet Oncology on February 16, 2010.

Complete Remission Predicts for Long Survival of Patients with Multiple Myeloma (03/12/2010)
Researchers from the M. D. Anderson Cancer Center have reported that achieving a complete remission (CR) was the dominant prognostic factor for long survival of patients with multiple myeloma (MM). The details of this large retrospective review were published in the March 2010 issue of Bone Marrow Transplantation.

Addition of Hormone Therapy to Radiation Improves Survival in Intermediate-risk, Early-stage Prostate Cancer (03/12/2010)
Researchers affiliated with the RTOG 94-08 clinical trial have reported that short-term androgen deprivation therapy (ADT) delivered before and during moderate-dose radiation therapy improves survival and reduces risk of recurrence compared with radiation alone in men with intermediate-risk, early-stage prostate cancer. The results of this Phase III study were presented at the 2010 Genitourinary Cancers Symposium in San Francisco on March 5-7.

Radiofrequency Ablation Effective For Small Renal Cell Carcinoma and Other Masses (03/11/2010)
Researchers from the M. D. Anderson Cancer Center have reported that radiofrequency ablation (RFA) is effective treatment for patients with renal masses, including renal cell carcinoma (RCC). The details of this study were presented at the 2010 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium March 5-7 in San Francisco.

Single-dose Neulasta® as Effective as Multiple-dose Neupogen® in Children with Sarcoma (03/11/2010)
Researchers involved in an international multicenter randomized trial have reported that single-dose Neulasta® (pegfilgrastim) is as effective as multiple-dose Neupogen® (filagrastim) for support of children receiving intensive chemotherapy for previously treated sarcoma. The details of this study were published in the March 10, 2010 issue of the Journal of Clinical Oncology.

Updated Survival Data on Provenge® for Treatment of Hormone Refractory Prostate Cancer Presented (03/11/2010)
Researchers affiliated with the IMPACT trial have reported that additional follow-up and more analyses demonstrate a clear survival advantage of Provenge® (sipuleucel-T) versus placebo in men with hormone-refractory prostate cancer. The details of this study were presented at the 2010 Genitourinary Cancers Symposium in San Francisco between March 5 and 7.

Oncotype DX® Predicts Recurrence Risk in Node-negative and Node-positive Breast Cancer Treated with Tamoxifen or Anastrozole (03/10/2010)
Researchers affiliated with the TransATAC Study have reported that the Oncotype DX® test predicts the risk of distant cancer recurrence in postmenopausal women with early, hormone receptor-positive breast cancer with both node-negative and node-positive disease treated with tamoxifen (Nolvadex®) or anastrozole (Arimidex®). These results were published early online in the Journal of Clinical Oncology on March 8, 2010.

Recent Results of High-dose Proleukin® for Metastatic Renal Cell Carcinoma Reported (03/10/2010)
Researchers involved in a U.S. multicenter trial (Cytokine Working Group) have reported that high-dose Proleukin® (aldesleukin, interleukin-2, IL-2) results in a higher response rate in patients with metastatic renal cell carcinoma (MRCC) than historically reported. The details of this study were presented at the 2010 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium, March 5-7, in San Francisco.

Cystoscopy Remains Best Method for Surveillance of Patients with Bladder Cancer (03/10/2010)
Researchers from the M. D. Anderson Cancer Center have reported that cystoscopy alone remains the most cost-effective method of detecting recurrent superficial bladder cancer. The details of this study were presented at the 2010 American Society of Clinical Oncology Genitourinary Cancers Symposium March 5-7 in San Francisco.

Combined Modality Therapy Spares Cystectomy in Majority of Patients with Locally Advanced Bladder Cancer (03/09/2010)
Researchers from the Massachusetts General Hospital have reported that 75% of patients with locally advanced bladder cancer can be treated successfully with combined modality therapy that preserves the bladder. The details of this 15-year study were presented at the 2010 American Society of Clinical Oncology Genitourinary Cancers Symposium March 5-7 in San Francisco.

Urinary Prostate Cancer Test, PCA3, Predictive of Biopsy Outcomes (03/09/2010)
Researchers involved in the international Reduction by Dutasteride of Prostate Cancer Events (REDUCE) trial have reported that the urinary PCA3 test can predict biopsy outcome in men taking dutasteride. The details of two studies were presented at the 2010 American Society of Clinical Oncology (ASCO) Genitourinary Cancer Symposium held in San Francisco, March 5-7.

HPV Vaccine Provides Little Benefit for Older Women (03/09/2010)
Researchers from Costa Rica have reported that women over the age of 40 are not likely to benefit from vaccination to prevent human papillomavirus (HPV). The details of this study were published in the March 3, 2010 issue of the Journal of the National Cancer Institute.

Avastin May Delay Progression of Ovarian Cancer (03/08/2010)
The results of a recent clinical trial suggest that a combination of Avastin® (bevacizumab) and chemotherapy, followed by maintenance treatment with Avastin, may result in better progression-free survival than chemotherapy alone in women with advanced ovarian cancer. Initial results of this Phase III clinical trial were made available in a press release from Genentech; full results will be presented at a future medical meeting.

Gene Signature Test May Help Predict Recurrences of Prostate Cancer After Prostatectomy (03/08/2010)
Researchers from the University of Texas at San Antonio, the University of Utah, and Myriad Genetics, Inc. have reported that a gene signature test performed on prostate cancer tissue can help predict the probability of recurrent disease in men with localized prostate cancer treated with radical prostatectomy. The details of this study were presented at the 2010 meeting of the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium March 5-7 in San Francisco.

Avastin® Not Contraindicated in Patients with CNS Metastases (03/08/2010)
Researchers from France have reported that patients with central nervous system (CNS) metastases have similar rates of whether or not they receive Avastin® (bevacizumab). The details of this study appeared in the January 2010 issue of Clinical Cancer Research.

Avastin Fails to Prolong Survival in Stomach Cancer (03/05/2010)
Avastin® (bevacizumab) in combination with chemotherapy does not extend overall survival in patients with inoperable, advanced, or metastatic stomach cancer, according to the results of a Phase III trial released by Roche.

Adjuvant Alfa Interferon Modestly Effective in High-risk Melanoma (03/05/2010)
Researchers from Italy have concluded, on the basis of a systematic review and meta-analysis, that adjuvant alpha interferon significantly improves disease-free survival (DFS) and overall survival (OS) in patients with high-risk melanoma. The details of this study appeared in an early online publication on February 23, 2010 in the Journal of the National Cancer Institute.

Cabazitaxel Effective for Hormone Refractory Prostate Cancer After Failure of Taxotere® (03/05/2010)
Researchers involved in the multicenter international Phase III trial (TROPIC) have reported that cabazitaxel (XRP-6258) was superior to Novantrone® (mitoxantrone) for the treatment of patients with hormone refractory prostate cancer (HRPC) who had failed treatment with Taxotere® (docetaxel). The details of this study were presented at the 2010 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium March 5-7 in San Francisco.

Combined Pelvic and Para-aortic Lymphadenectomy Recommended for Intermediate and High-risk Endometrial Cancer (03/04/2010)
Researchers from Japan have reported that women with intermediate and high-risk endometrial cancer have a better survival following combined pelvic and para-aortic lymphadenectomy compared with pelvic lymphadenectomy alone. The details of this study were published early online on February 25, 2010 in the Lancet.

Bisphosphonates for Osteoporosis Treatment May Decrease Risk of Breast Cancer (03/04/2010)
Researchers from the University of Wisconsin have reported that the use of bisphosphonates for osteoporosis treatment may reduce the risk of developing breast cancer. The details of this study were published in the March 1, 2010 issue of the British Journal of Cancer.